Traws Pharma Inc (TRAW) - Total Liabilities
Based on the latest financial reports, Traws Pharma Inc (TRAW) has total liabilities worth $13.47 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Traws Pharma Inc growing its equity to track the company's year-over-year net asset growth rate.
Traws Pharma Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Traws Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See TRAW cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Traws Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Traws Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Straits Inter Logistics Bhd
KLSE:0080
|
Malaysia | RM544.46 Million |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
Germany | €39.26 Million |
|
Pool Advista Indonesia Tbk
JK:POOL
|
Indonesia | Rp11.50 Billion |
|
Credit Intelligence Ltd
AU:CI1
|
Australia | AU$219.31K |
|
Apptech Corp
NASDAQ:APCX
|
USA | $3.52 Million |
|
Seafarms Group Ltd
AU:SFG
|
Australia | AU$23.30 Million |
|
REFINED METALS CORP. O.N.
F:CWA0
|
Germany | €835.68K |
Liability Composition Analysis (2011–2025)
This chart breaks down Traws Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TRAW market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Traws Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Traws Pharma Inc (2011–2025)
The table below shows the annual total liabilities of Traws Pharma Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.25 Million | -80.13% |
| 2024-12-31 | $56.59 Million | +371.17% |
| 2023-12-31 | $12.01 Million | +8.57% |
| 2022-12-31 | $11.06 Million | +18.22% |
| 2021-12-31 | $9.36 Million | -32.24% |
| 2020-12-31 | $13.81 Million | +14.14% |
| 2019-12-31 | $12.10 Million | -3.48% |
| 2018-12-31 | $12.54 Million | -20.86% |
| 2017-12-31 | $15.84 Million | -12.52% |
| 2016-12-31 | $18.11 Million | +43.64% |
| 2015-12-31 | $12.61 Million | -46.85% |
| 2014-12-31 | $23.71 Million | -2.22% |
| 2013-12-31 | $24.25 Million | -89.98% |
| 2012-12-31 | $242.16 Million | +69.48% |
| 2011-12-31 | $142.88 Million | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more